Life Sciences Industry Outlook 2017 has been saved
Life Sciences Industry Outlook 2017
What are the trends for US life sciences in the coming year?
Amid pricing pressures, regulatory changes, emerging innovations, and patient-centric models, growth opportunities remain for life sciences companies in 2017. Explore the trends impacting life sciences companies in the coming year and beyond.
- Key opportunities
- 2017 Global Life Sciences Outlook
- Watch 2017 MedTech videos
- Additional perspectives
- Latest trends in health care
Key opportunities, trends, and challenges in the US life sciences industry
Managing costs, innovative partnerships, customer engagement, and a changing regulatory environment are all part of the shifting landscape facing life sciences companies in 2017. In this podcast interview, Greg Reh, US/global Life Sciences sector leader, shares his perspectives on trends impacting life sciences companies in 2017.
Collaboration becomes the key theme in 2017—collaboration within the health care ecosystem, with patients, or internally. Many of the pressures that life sciences companies are under—whether they cost or regulatory or operational—in somewhere, shape, or form, can be de-risked by creating a platform for information and idea exchange.
Listen to hear more about industry trends impacting life sciences companies
2017 US Life Sciences Outlook: Look again at the opportunities
How is the global life sciences sector addressing today’s evolving marketplace, one characterized by economic uncertainty, cost and pricing pressures, increased demand for innovation and value, more focus on consumer engagement, and an ever-changing regulatory and risk environment?
Greg Reh, US and Global Life Sciences sector leader, shares his perspectives on trends impacting life sciences companies in 2017.
Key discussion points include:
- Reconciling pricing pressures with awareness of what it costs to bring innovative products to market
- Understanding the possible implications of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) on life sciences companies
- Developing real-world evidence capabilities to demonstrate value
- Adapting to patient-centered models through advancements in technology
- Advancing partnerships and collaboration across the health care landscape through translational medicine and open innovation models
- Navigating a shifting global and national regulatory landscape such as Identification of Medicinal Products (IDMP)
- Collaboration and opportunities for information and idea exchange
2017 US Life Sciences Outlook: Explore the next generation of medical technology
What opportunities and trends are on the horizon for the medical technology industry? Watch Glenn Snyder, Deloitte's US MedTech segment leader, discuss more details about trends in the medical technology industry in the latest 2017 MedTech Outlook videos.
"The overall increase in collaboration between the life sciences industry, the payers, and providers will certainly have a positive impact both on outcomes as well as costs."
- Greg Reh
Additional perspectives on life sciences and health care trends
Life sciences sector growth is closely tied to global health care expenditures which, in 2017 and successive years, are expected to be fueled by increasing demand from an aging population and the burgeoning prevalence of chronic and communicable diseases. This 2017 outlook reviews the current state of the global life sciences sector; explores trends and issues impacting market segments and individual
Life Sciences Regulatory Outlook
Life sciences companies should prepare to face continued uncertainty in the regulatory landscape in 2017. With drug pricing in flux and regulations aimed at improving patient outcomes and value-based
Global Health Care Outlook
An aging global population and chronic diseases are fueling the rising demand and associated spending of care and an increasing patient awareness, knowledge, and expectations are putting pressure on the development of costly clinical innovations. The Global Health Care Outlook explores trends and issues impacting sector organizations; and suggests considerations for stakeholders as they seek to deliver cost-effective high-value health care.
What might Donald Trump’s election mean for health care?
In November, Donald Trump was elected the 45th president of the United States and the Republicans retained majorities in both the Senate and the House. What does this portend for our health care system?
President-elect Trump ran on one main policy issue related to health care – to repeal the Affordable Care Act (ACA). Could he, together with a Republican-led Congress, do this? And what might his election mean more broadly for health insurance exchanges, value-based care initiatives, and consumers’ and
In today’s rapidly evolving marketplace environment, key business issues are converging with impacts felt across multiple industry sectors. What are the key trends, challenges, and opportunities that may affect your business and influence your strategy? Look for more perspectives and insights from some of Deloitte’s forward thinkers.